Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
This article was originally published in The Gray Sheet
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
You may also be interested in...
Lab diagnostic products will actually account for a larger portion of Hologic’s business post-acquisition than the firm’s core mammography, ultrasound and magnetic resonance imaging offerings.
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
China Medical Technologies is acquiring a human papillomavirus genotyping assay which it expects will generate up to $26.5 million in sales next year